 |
|
|
|
This month we would like to know...
Egrifta (tesamorelin) was recently FDA-approved to treat HIV-associated lipodystrophy (aka, visceral adipose tissue [VAT]), which will be available in January 2011. VAT has been associated with adverse cardiovascular outcomes. How is your health-system covering or planning on covering this injectable drug product?
| a) |
We will be/are covering it as a medically necessary drug if patient's meet criteria for use. |
| |
|
| b) |
We will be/are covering it as a medically necessary drug for all HIV patients. |
| |
|
| c) |
We will not be covering it at all since it is a cosmetic product. |
| |
|
| d) |
We have not yet decided how to cover this product. |
| |
|
Vote in our survey, and see what other P&T committee members have to say.
 |
|
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary.
Formulary
Digital Edition
Click here to view the current edition.
Click here to subscribe. |
|
|
|
|
Formulary’s Enewsletter Is Going Weekly
With this issue, Formulary is introducing weekly enewsletters. Formulary would like your feedback on this first issue. Click here to provide comments. |
FDA begins process to remove breast cancer indication from Avastin label
FDA is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use. More... |
|
Combination improves tumor response rates in patients with HER2-positive breast cancers
A combination of lapatinib, trastuzumab, and paclitaxel significantly improved tumor response rates in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancers, according to a new study presented at the annual Cancer Therapy and Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium held recently in San Antonio, Texas. More... |
|
| |
Kombiglyze XR tablets approved for the treatment of type 2 diabetes mellitus in adults
FDA has approved saxagliptin and metformin XR (Kombiglyze XR, AstraZeneca and Bristol-Myers Squibb) tablets for the treatment of type 2 diabetes in adults. Kombiglyze XR is the first and only once-a-day metformin XR plus DPP-4 inhibitor combination tablet offering strong glycemic control across glycosylated hemoglobin levels, fasting plasma glucose and post-prandial glucose. More... |
|
| |
| |
Wholesale, retail level recalls
In consultation with FDA, McNeil Consumer Health, Division of McNeil-PPC Inc., has initiated a wholesale and retail level recalls. With this: In consultation with FDA, McNeil Consumer Health, Division of McNeil-PPC Inc., has initiated wholesale and retail level recalls. More... |
FDA panel recommends approval of weight-loss drug
An FDA panel has recommended that the agency approve Orexigen Therapeutics’ and Takeda’s obesity drug Contrave (naltrexone SR/bupropion SR). This makes the drug the first in a group of competitors to receive this recommendation, the Associated Press reported. More... |
| THERAPY UPDATE |
Nonanthracycline regimens for adjuvant treatment of operable breast cancer
Nonanthracycline-containing chemotherapy regimens for the adjuvant treatment of operable stage I to III breast cancer are discussed, including efficacy and toxicity results from recent randomized clinical trials comparing anthracycline to nonanthracycline-containing regimens. More... |
Top 5 Web Stories:
Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia
Attention deficit hyperactivity disorder: More than a child's disease
FDA Actions in Brief November 2010 (Latuda, Ofirmev, Cymbalta, Botox, Pradaxa, Afinitor, Teflaro, Herceptin, Kapvay)
Olmesartan medoxomil, amlodipine, and hydrochlorothiazide (Tribenzor): A new 3-drug combination product for the treatment of hypertension
FDA Pipeline Preview, November 2010 (Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol extended-release oral analgesic, AVP-21D9, 1% tenofovir vaginal gel, AFM 13, hGH-CTP, Rozrolimupab, Nefecon, SB1518 JAK2 inhibitor)
|
|
|
|
|
|
| |
